As predicted in a February STAT opinion piece (bit.ly/3qlykH3) by Aldatu’s CEO, Dr. Iain MacLeod, The New York Times reports that “Reaching ‘Herd Immunity’ Is Unlikely in the U.S.” nytimes.com/2021/05/03/hea…

For everyone surprised by the The New York Times piece predicting the US will not reach herd immunity, here's a reminder that pathologist and entrepreneur Iain MacLeod of Aldatu Biosciences made the same call back in February (and endured a lot of pushback for it): bit.ly/3qlykH3

We can not believe that many of the papers highlighted by Nature were from South Africa. We would never dream to have created a network and consortium in Africa to advance global science. We feel so honored and humbled that we could help the world to face this pandemic...

Confirmed Detection of eight (8) more genomes B.1.617.2 and two (2) community transmission of B.1.1.7 in South Africa, By Network for Genomic Surveillance in South Africa (NGS-SA), 13 May 2021

Interested in #Biotechnology? Tune in to this week's episode of the "When Science Speaks" #podcast to get insights from iain, Co-Founder, CEO, and Chief Scientific Officer Aldatu Biosciences: #vaccines, #publichealth and more. bit.ly/WhenScienceSpe…

Aldatu's variant testing now differentiates 8 key variants - including the new Delta variant - in under two hours. Check out the product page aldatu.bio/variants or email [email protected] #covid #testing #change

Help Save Lives I'm participating in ResearcHERS: Women Fighting Cancer of Eastern New England to raise money for the American Cancer Society. Could you support me by making a donation? ⁦American Cancer Society⁩ mobileacs.org/454asm

We’re seeking a highly-motivated and talented Senior Research Associate to join our Assay Development team to work on developing the first universal diagnostic for Crimean-Congo hemorrhagic fever, recognized as a significant pandemic risk aldatu.bio/careers

This #WorldAidsDay2021, as we work tirelessly to end the #COVID19 pandemic, let us not forget that there's still much to be done to end the 40-year AIDS epidemic.

"You might call it an insurance policy against unknowns, because you don't have to change the design of your test in the future to compensate for changes," - Iain MacLeod, Aldatu CEO.

This month's Harvard Innovation Labs 10 for 10 list features innovations that help people enhance and plan their lives in a variety of ways — from improving outcomes for people who want to quit smoking to offering compassionate end-of-life planning. innovationlabs.harvard.edu/about/news/10-…

aldatu.bio/careers to find out more and apply!

#grants & awards ~Ontogen Medtech awarded $258k Phase I This account is no longer active #SBIRGrant to develop #PulmonaryEmbolism #catheter ~Marker Therapeutics, Inc. awarded $2M #FDA #grant from to support Phase 2 #ARTEMIS Trial ~Aldatu Biosciences awarded a $3M America's Seed Fund #grant from the @NIAIDFunding

Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio - development of a universal, pan-lineage detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV), the causative agent of Crimean Congo Hemorrhagic Fever (CCHF). aldatu.bio/cchfv

Thank you, labguru !

Aldatu has received $3M from the National Institute of Allergy and Infectious Diseases at the NIH to create the first universal molecular diagnostic for the simultaneous detection and differentiation of all variants of #Ebolavirus and #Marburg virus. aldatu.bio/filoviruses